Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR
Clinical Research in Cardiology · 2025
DOI: 10.1007/s00392-025-02749-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von David Hesselbarth und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Hugstetter Str. …. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Fibrin, Aortic Valve Stenosis, Blood Coagulation. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Haemonetics Corporation, Albert-Ludwigs-Universität Freiburg im Breisgau.
Abstract (Originalsprache)
Background
Patients after transcatheter aortic valve replacement (TAVR) are at increased risk of both major adverse cardiac events (MACE), including ischemic and thrombotic complications, as well as significant bleeding. Given this delicate balance between prothrombotic and hemorrhagic risk, the assessment of hemostatic markers might help identify patients at increased risk.
Aim
To identify hemostatic markers associated with MACE and bleeding following TAVR.
Methods
In this prospective single-center cohort study, of patients undergoing TAVR from November 2020 to June 2022, the association of hemostatic profiles and clinical outcomes was assessed. The profiling included thromboelastography (TEG), light transmission aggregometry (LTA), and conventional laboratory markers to assess thrombogenicity. The outcome was MACE (death, myocardial infarction, or stroke) and major/non-major clinically relevant bleeding at 6 months.
Results
Of the 107 patients included, 104 completed follow-up. At 6 months, 9% experienced MACE, and 10% had clinically relevant bleeding. Platelet–fibrin clot strength, reflected by the maximum amplitude (MA-citrated kaolin) in thrombelastography, was elevated in patients with MACE (per 1 mm increase: HR 1.26 [1.02;1.56], p = 0.03). Fibrin’s role in the maximum clot strength was crucial. Elevated fibrinogen levels, increased citrated functional fibrinogen (MA-CFF), and faster fibrin formation (alpha-angle[α]) associated with a higher risk of MACE (per 20 mg/dL fibrinogen increase: HR 1.15 [1.02–1.28], p = 0.02; per 5 mm MA-CFF increase: HR 1.59 [1.12–2.26], p < 0.01; per degree α-citrated rapid TEG increase: HR 1.55 [1.10–2.19], p = 0.01), respectively. High on-treatment ADP-induced platelet reactivity assessed by LTA was associated with a lower risk of major and non-major clinically relevant bleeding at 6 months (per 10% MA-ADP increase: HR 0.66 [0.47;0.93] p=0.02 ).
Conclusion
Selected hemostatic markers associated with the risk of MACE and bleeding within 6 months in patients post-TAVR, with fibrin clot strength identified as a principal marker. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. david.hesselbarth@uniklinik-freiburg.de.
- Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
- Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
- Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Heidelberg, Germany.
- European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Mannheim, Germany.
Förderung
- Haemonetics Corporation
- Albert-Ludwigs-Universität Freiburg im Breisgau
Zitieren
APA
Hesselbarth, D., D'Orazio, M., Ciccarone, G., Gjermeni, D., Jülch, C., Wessinger, M., Maslarska, M., Rilinger, J., Hilgendorf, I., Wolf, D., Kaier, K., Duerschmied, D., Pottgiesser, T., von Zur Mühlen, C., Westermann, D., & Olivier, C. B. (2025). Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02749-7
Vancouver
Hesselbarth D, D'Orazio M, Ciccarone G, Gjermeni D, Jülch C, Wessinger M, et al. Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-025-02749-7
BibTeX
@article{Hesselbarth2025,
author = {Hesselbarth, David and D'Orazio, Michelle and Ciccarone, Giovanni and Gjermeni, Diona and Jülch, Carina and Wessinger, Marius and Maslarska, Mariya and Rilinger, Jonathan and Hilgendorf, Ingo and Wolf, Dennis and Kaier, Klaus and Duerschmied, Daniel and Pottgiesser, Torben and von Zur Mühlen, Constantin and Westermann, Dirk and Olivier, Christoph B},
title = {Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR},
journal = {Clinical Research in Cardiology},
year = {2025},
doi = {10.1007/s00392-025-02749-7}
}
EUVIMED